bioRxiv Science⌕ Search

Biology subjects

Twarog, N. A.

Publications and source records attributed to Twarog, N. A..

2 recordsLinked to original sources

rtmsEcho: An Open-Source R Package for Automated Analysis of Acoustic Ejection Mass Spectrometry Data

Mass spectrometry (MS) is a well-established technology in biological research, enabling sensitive and precise quantitative analysis of complex samples. While traditional LC-MS systems provide robust performance for targeted analyses, their reliance on chromatographic separation limits throughput, rendering large-scale studies inefficient. The emergence of acoustic ejection mass spectrometry (AEMS) has revolutionized high-throughput workflows by eliminating chromatography and enabling direct nanoliter-scale sampling, achieving hundreds to thousands of measurements per hour. However, AEMSs full potential remains constrained by software limitations--existing tools lack robust automated processing capabilities for critical tasks such as peak detection, integration, and multimodal data analysis (e.g., multiple reaction monitoring, precursor ion, and neutral loss scans). To address this gap, we developed rtmsEcho, an open-source R package that extends our previously published rtms framework. This specialized solution provides direct access to AEMS data, enabling customizable processing of both MRM and full-scan acquisitions (precursor ion and neutral loss modes) while automating shot-to-peak association and spectral analysis. By streamlining data extraction and quantification, rtmsEcho enhances efficiency and reproducibility in high-throughput applications, including drug discovery, quality control, and clinical diagnostics. This innovation bridges a critical gap in AEMS data analysis, allowing researchers to fully leverage the speed and precision of next-generation mass spectrometry.

biochemistry↗

A screen to identify antifungal antagonists reveals a variety of pharmacotherapies induce echinocandin tolerance in Candida albicans.

Through screening a comprehensive collection of drugs approved for human use, we identified over 20 that oppose the antifungal activity of the echinocandins upon the infectious yeast, Candida albicans. More detailed evaluation of five such drugs, including the atypical antipsychotic aripiprazole and the tyrosine kinase inhibitor ponatinib, indicated they promote C. albicans survival following exposure to the echinocandin antifungals. The activity of the five selected antagonists was dependent upon the Mkc1p MAPK pathway, however, ponatinib was paradoxically shown to suppress phosphorylation and therefore activation of Mkc1p itself. Components of several other signaling pathways are also required, including those of calcineurin and casein kinase-2, suggesting the observed antagonism required much of the cell wall stress responses previously described for C. albicans. Transcriptome analysis revealed that the antagonists stimulated the expression of genes involved in xenobiotic and antifungal resistance, and suppressed the expression of genes associated with hyphal growth. Thus, the echinocandin antagonistic drugs modulate C. albicans physiology in ways that could impact its pathogenicity and/or response to therapeutic intervention. Finally, a mutant lacking the Efg1p transcription factor, which has a central role in the activation of C. albicans hyphal growth was found to have intrinsically high levels of echinocandin tolerance, suggesting a link between modulation of morphogenesis related signaling and echinocandin tolerance. ImportanceWe report a substantial number of previously unknown drug interactions that modulate the echinocandin sensitivity of one of the most prevalent human fungal pathogens, Candida albicans. The echinocandins are the first line therapy for treating disseminated and often lethal Candida infections, that account for >75% of invasive fungal infections in the U.S.. For largely unknown reasons, a substantial number of patients with invasive candidiasis fail to respond to treatment with these drugs. The finding of this study suggest that co-administered medications have the potential to influence the therapeutic outcomes of invasive fungal infections through modulating antifungal drug tolerance and/or fungal pathogenicity. The potential for echinocandin antagonistic medications to influence therapeutic outcomes is discussed.

microbiology↗